Ironwood Pharmaceuticals to acquire Switzerland-based VectivBio for $1bn
VectivBio’s lead investigational product is apraglutide, a next-generation, long-acting synthetic GLP-2 analog in phase 3, which is being…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
23 May 23
VectivBio’s lead investigational product is apraglutide, a next-generation, long-acting synthetic GLP-2 analog in phase 3, which is being…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
23 May 23
Switzerland-based Novartis will pay AVROBIO $87.5m in cash at closing as compensation for the sale and transfer of…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 May 23
According to the terms of the contract, Croda will purchase a licence from Amyris to market, distribute, and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
12 May 23
Bentracimab is a novel, monoclonal antibody fragment that reverses the antiplatelet activity of ticagrelor, an antiplatelet medicine marketed…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
11 May 23
The transaction, which has been unanimously approved by the Board of Directors of both the companies, is expected…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
09 May 23
The transaction includes BPS’ manufacturing facilities, along with around 1,700 employees working in Bloomington, Indiana and Halle, Germany,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
01 May 23
Iveric Bio is a US-based biopharmaceutical company focused on novel therapies for ophthalmologic diseases and is currently developing…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
25 Apr 23
Baqsimi is a nasally administered glucagon, indicated for the treatment of severe hypoglycaemia (very low blood sugar) in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
24 Apr 23
The merger creates a combined company that will operate as GRI Bio and will focus on advancing the…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
20 Apr 23
Polivy (polatuzumab vedotin-piiq) in combination with Rituxan (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) is indicated for the…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates